Rigel Projects Q4 EPS +66% to $1.33 on $69.8M Revenue, Estimate Revisions Surge
Rigel Pharmaceuticals projects Q4 EPS of $1.33, up 66.3% year-over-year, on revenues of $69.81 million, a 21.2% increase. Consensus EPS estimates rose 30.4% in 30 days, but a negative 0.75% Earnings ESP and Zacks Rank #3 signal limited beat probability.
1. Q4 Earnings Forecast
Rigel expects Q4 EPS of $1.33, up 66.3% year-over-year, on revenues of $69.81 million, a 21.2% increase over the year-ago quarter.
2. Consensus Estimate Revisions
Analysts have raised the consensus EPS estimate by 30.43% over the last 30 days, reflecting improved expectations ahead of the earnings release.
3. Earnings ESP and Beat Probability
The Most Accurate Estimate trails the consensus, producing a 0.75% Earnings ESP and paired with a Zacks Rank #3, suggesting lower odds of an earnings beat.
4. Historical Earnings Surprises
Rigel has beaten consensus EPS estimates in each of the past four quarters, most recently delivering a 56.99% positive surprise.